Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation

Abstract Background To date, there is no information on the safety and efficacy of the novel anti-sarbecoviruses monoclonal antibody sotrovimab administered, as a post-exposure prophylactic measure, during the aplastic phase of autologous stem cell transplantation (ASCT). Methods We describe the out...

Full description

Bibliographic Details

Published in:	Infectious Agents and Cancer
Main Authors:	Gianpaolo Marcacci, Nicola Coppola, Emanuela Madonna, Cristina Becchimanzi, Stefania De Pascalis, Silvia D’Ovidio, Stefania Crisci, Piera Maiolino, Rosaria De Filippi, Antonio Pinto
Format:	Article
Language:	English
Published:	BMC 2022-08-01
Subjects:	Multiple myeloma Autologous stem cell transplantation SARS-CoV-2 Omicron variant Sotrovimab
Online Access:	https://doi.org/10.1186/s13027-022-00454-y